Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
Earnings Data
Report Date
Apr 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.07Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong program-level progress and meaningful financial discipline: multiple regulatory and clinical catalysts are in motion (Sonata enrollment, potential Zynquista resubmission, pilovapitan Phase III readiness, LX9851 milestones), operating expenses and losses were substantially reduced, and the company strengthened its cash position post-period. Offsetting risks include reliance on third-party STENO-1 data for Zynquista, modest INPEFA sales, a reduced year-end cash balance prior to the subsequent raise, and the need to partner to advance pilovapitan into Phase III. On balance, the positive pipeline and financial improvements materially outweigh the remaining execution and external-data risks.Company Guidance
Strong pipeline momentum with multiple late-stage programs
Advancing three late-stage programs (sotagliflozin, pilovapitan, LX9851) across cardiometabolic disease and chronic pain with multiple near-term catalysts in 2026–2027; company emphasizes potential for first-in-class opportunities and transformative patient impact.
Sonata HCM Phase III enrollment progress
Sonata HCM (sotagliflozin) surpassed 50% enrollment and is being conducted at 130+ sites across ~20 countries; company expects enrollment completion by mid-2026 and top-line results in 2027.
Zynquista (sotagliflozin) path to NDA resubmission
FDA feedback indicates the investigator-initiated STENO-1 study may support an NDA resubmission for Zynquista in type 1 diabetes; Lexicon plans a resubmission in 2026 with an expected ~6-month review and potential approval later in 2026, contingent on STENO-1 patient exposure and DKA safety data.
Pilovapitan end-of-Phase II success and Phase III readiness
Received a successful end-of-Phase II meeting with FDA for pilovapitan (DPNP) with no objections to advancing into Phase III; proposed registrational program: two placebo-controlled 12-week studies (10 mg vs placebo); >600 patients previously treated with pilovapitan supporting safety/tolerability.
LX9851 progress and milestone revenue
Novo Nordisk-triggered milestone payment of $10 million in February for LX9851 (obesity); Lexicon has fully handed off development to Novo and may receive an additional $20 million in milestones in 2026; recent publication highlighted mechanism (ACSL5 inhibition).
Material reductions in operating costs
Operating expense improvements: R&D FY 2025 down to $61.1M from $84.5M (≈-27.7%); R&D Q4 down to $11.3M from $26.7M (≈-57.7%); SG&A FY 2025 down to $37.3M from $143.1M (≈-73.9%); SG&A Q4 down to $8.8M from $32.3M (≈-72.8%). Company reports operating expenses down $129.5M year-over-year.
Improved loss metrics and balance sheet actions
Net loss narrowed materially: Q4 2025 net loss $15.5M vs $33.8M prior-year (loss reduced ≈54.1%); FY 2025 net loss $50.3M vs $200.4M prior-year (loss reduced ≈74.9%). Company reduced total debt by ≈$46.3M in 2025 and subsequently strengthened cash by >$100M via equity sales and a Novo milestone.
FY and Q4 revenue driven by licensing
Total revenues: Q4 2025 $5.5M (includes $4.3M licensing from Novo Nordisk; INPEFA net sales $1.1M); FY 2025 $49.8M (includes $45M licensing from Novo Nordisk; INPEFA net sales $4.6M). Licensing is a major near-term revenue driver.
LXRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LXRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 05, 2026 | $1.63 | $1.64 | +0.61% |
Nov 06, 2025 | $1.38 | $1.43 | +3.62% |
Aug 06, 2025 | $1.05 | $1.15 | +9.52% |
May 13, 2025 | $0.63 | $0.53 | -15.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lexicon Pharmaceuticals (LXRX) report earnings?
Lexicon Pharmaceuticals (LXRX) is schdueled to report earning on Apr 30, 2026, Before Open (Confirmed).
What is Lexicon Pharmaceuticals (LXRX) earnings time?
Lexicon Pharmaceuticals (LXRX) earnings time is at Apr 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LXRX EPS forecast?
LXRX EPS forecast for the fiscal quarter 2026 (Q1) is -0.04.